This symposium convenes oncology professionals, researchers, and policy advocates to explore the current challenges and strategic solutions in advancing inclusive excellence across the cancer research continuum. Attendees will engage with thought leaders discussing policy-aligned models for accountability, tools for building diversity plans into clinical trial design, and methods for standardizing demographic reporting in academic publications.

With a focus on practical implementation, the DRIVE Initiative offers a blueprint to help institutions, sponsors, and investigators align with regulatory guidance, such as the U.S. FDORA Act of 2022, while advocating for its broader international adoption. This is more than an academic discussion; it's a call to action for stakeholders committed to advancing equitable outcomes in cancer care and research.

A 3-hour symposium with presentations for community oncologists, preceding the ASH Annual Meeting.

Innovative immune effector therapies, including CAR T-cell and bi-specific antibody treatments, have transformed cancer care but remain largely inaccessible to community oncology practices. Our NETWORK is dedicated to bridging this gap by establishing the necessary infrastructure, protocols, and training to safely and effectively administer these lifesaving therapies in community settings. By promoting equitable access, fostering clinical trial participation, and supporting diverse patient populations, we aim to reduce disparities and expand the reach of modern cellular therapies.